

CONTINUING EDUCATION

Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia

ACPE# 0809-9999-10-114-H01-P

(Pharmacotherapy 2010;30(9 Pt 2):102S–104S)

Release Date: September 1, 2010

Expiration Date: September 1, 2011

Faculty

Andrea Iannucci, Pharm.D.
University of California–San Francisco School of Pharmacy
University of California–Davis Medical Center
Sacramento, California

Kamakshi V. Rao, Pharm.D.
Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, North Carolina

Elias Jabbour, M.D.
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Target Audience

This educational activity is designed for pharmacists involved and/or interested in the management of patients with chronic myeloid leukemia (CML).

Overview

This journal supplement provides an overview of the pathophysiology, current management strategies, and future directions in CML.

Educational Objectives

On successful completion of this educational activity, participants should be able to:

- Discuss recent clinical trial data evaluating the use of tyrosine kinase inhibitors in the management of patients with newly diagnosed CML so that the optimal timing and dosage of therapy can be implemented on an individual patient basis.
- Describe standards for determining failure of front-line therapy.
- Discuss the importance of clinical and molecular features in determining second-line therapy in order to appropriately manage patients with chronic-phase CML who have experienced a suboptimal response or intolerance to front-line tyrosine kinase inhibitor therapy.
- Evaluate the impact of adverse-event profiles in selecting second-line therapeutic agents for patients with chronic-phase CML in order to maximize clinical response and limit toxicity.
- Discuss the importance of molecular monitoring in CML.
- Compare molecular monitoring to cytogenetic monitoring.

Sponsorship

This activity is jointly sponsored by Postgraduate Institute for Medicine and prIME Oncology.

Accreditation Statement



Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education (CE) activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0809-9999-10-114-H01-P)

Type of Activity

Knowledge

Support Statement

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies used in this activity, and patient care recommendations. Postgraduate Institute for Medicine is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in health care and is not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse or life partner have with commercial interests related to the content of this CE activity:

Kamakshi V. Rao, Pharm.D.	Stockholder: Pfizer Inc.
Andrea Iannucci, Pharm.D.	No real or apparent conflicts to disclose
Elias Jabbour, M.D.	Consultant: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation Speakers' bureau: Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse or life partner have with commercial interests related to the content of this CE activity:

The following Postgraduate Institute for Medicine planners, managers, and reviewers—Jan Hixon, R.N., B.S.N., M.A., Trace Hutchison, Pharm.D., Julia Kimball, R.N., B.S.N., Samantha Mattiucci, Pharm.D., Jan Schultz, R.N., M.S.N., CCMEP, and Patricia Staples, M.S.N., N.P.-C., CCRN—hereby state that they or their spouse or life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following medical writers and editors—Sabeeha Muneer, Ph.D., Laurel McKee Ranger, Kathryn Brown Charalambous, Ph.D., and Trudy Stoddert, ELS—have no real or apparent conflicts of interest to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. During the period of September 1, 2010–September 1, 2011, participants must read the learning objectives and faculty disclosures and study the educational activity.

Postgraduate Institute for Medicine supports Green CE by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 7347. On registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets/year.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the United States Food and Drug Administration. Postgraduate Institute for Medicine, prIME Oncology, and the supporters of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Institute for Medicine or prIME Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Although it offers CE contact hours, this activity is not intended to provide extensive training or certification in the field.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, drugs, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.